InMed Pharmaceuticals to be Acquired by Capstone Development
Ticker: INM · Form: 8-K · Filed: Oct 23, 2024 · CIK: 1728328
Sentiment: neutral
Topics: acquisition, going-private, merger
TL;DR
InMed is getting bought by Capstone Development, going private in Q1 2025.
AI Summary
InMed Pharmaceuticals Inc. announced on October 22, 2024, that it has entered into a definitive agreement to be acquired by Capstone Development, LLC. The transaction is expected to close in the first quarter of 2025, subject to customary closing conditions. This acquisition marks a significant event for InMed as it transitions to a private entity.
Why It Matters
This acquisition signifies a major change in InMed Pharmaceuticals' corporate structure, moving from a publicly traded company to a private one under Capstone Development's ownership.
Risk Assessment
Risk Level: medium — The acquisition is subject to closing conditions, and the transition to a private company may involve unforeseen challenges.
Key Players & Entities
- InMed Pharmaceuticals Inc. (company) — Company filing the report and being acquired
- Capstone Development, LLC (company) — Acquiring company
- October 22, 2024 (date) — Date of the definitive agreement
- first quarter of 2025 (date) — Expected closing period for the acquisition
FAQ
What is the nature of the agreement between InMed Pharmaceuticals Inc. and Capstone Development, LLC?
InMed Pharmaceuticals Inc. has entered into a definitive agreement to be acquired by Capstone Development, LLC.
When is the acquisition of InMed Pharmaceuticals Inc. expected to be completed?
The acquisition is expected to close in the first quarter of 2025.
What are the conditions for the closing of the acquisition?
The acquisition is subject to customary closing conditions.
What is the filing date of this Form 8-K?
This Form 8-K was filed as of October 23, 2024.
What is the principal executive office address for InMed Pharmaceuticals Inc.?
The address of InMed Pharmaceuticals Inc.'s Principal Executive Offices is Suite 1445 - 885 W. Georgia Street, Vancouver, B.C. Canada V6C 3E8.
Filing Stats: 558 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2024-10-23 12:28:16
Filing Documents
- ea0218323-8k_inmed.htm (8-K) — 27KB
- ea021832301ex99-1_inmed.htm (EX-99.1) — 13KB
- ex99-1_001.jpg (GRAPHIC) — 5KB
- 0001213900-24-089887.txt ( ) — 222KB
- inm-20241022.xsd (EX-101.SCH) — 3KB
- inm-20241022_lab.xml (EX-101.LAB) — 33KB
- inm-20241022_pre.xml (EX-101.PRE) — 22KB
- ea0218323-8k_inmed_htm.xml (XML) — 4KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On October 22, 2024, the Company announced the appointment of Dr. Barry Greenberg, to its Scientific Advisory Board. Dr. Greenberg is the Director of the Alzheimer's Disease Translational Center and an Associate Professor in the Department of Neurology at the Johns Hopkins University School of Medicine. The information set forth in this Item 7.01, including Exhibits 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. The information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits: The following exhibits shall be deemed to be furnished, and not filed: Exhibit No. Description 99.1 News release, dated October 22, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document and included as Exhibit 101) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INMED PHARMACEUTICALS INC. Date: October 22, 2024 By: /s/ Eric A Adams Eric A Adams President & CEO 2